Publications

5674 Results

Individual prediction of prostate cancer based on prostate specific antigen

Authors
C Chi;D Pauler Ankerst;P Goodman
Journal / Conference
Clinical Trials 2 (Suppl 1):P40
Year
2005
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Gene expression distinguishes Burkitt Lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens

Authors
SS Dave;K Fu;G Wright;L Lam;TC Greiner;DD Weisenberger;PM Kluin;E Boerma;A Rosenwald;G Ott;HK Muller-Hermelink;RD Gascoyne;J Delabie;LM Rimsza;RM Braziel;TM Grogan;E Campo;ES Jaffe;J Vose;JO Armitage;JM Connors;EB Smeland;S Kvaloy;H Holte;TP Miller;RI Fisher;E Montserrat;WH Wilson;M Bahl;H Zhao;L Yang;J Powell;R Simon;WC Chan;LM Staudt
Journal / Conference
Blood 106(11):#415
Year
2005
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8819

S9900: Preliminary "surgical" results of a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC)

Authors
E Vallieres;KMW Pisters;J Crowley;K Chansky;P Bunn;D Gandara
Journal / Conference
Lung Cancer 49 (Suppl 2):S43 (0-124)
Year
2005
Research Committee(s)
Lung
Study Number(s)
S9900

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial

Authors
RD Etzioni;N Howlader;PA Shaw;DP Ankerst;DF Penson;PJ Goodman;IM Thompson
Journal / Conference
Journal of Urology 174:877-881
Year
2005
Research Committee(s)
Cancer Control
Study Number(s)
SWOG-9217

Incidence, outcomes, and SNP genotypes show different ethnic association in patients with myeloma, assessed in SWOG and ECOG clinical trials S9321 and E9486: from the Bank on a Cure

Authors
B Van Ness;J Crowley;C Ramos;S Grindle;E Rasmussen;E Blood;A Hoering;B Barlogie;P Greipp;B Durie
Journal / Conference
Blood (ASH Annual Meeting Abstracts) 106(11): #506
Year
2005
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

SNP genotypes show association with common toxicities during both VAD induction and high dose melphalan with autologous transplant support in Intergroup trial S9321 for myeloma: from the bank on a cure

Authors
BG Van Ness;JC Crowley;C Ramon;S Grindle;E Rasmussen;A Hoering;P Greipp;B Barlogie;B Durie
Journal / Conference
Blood (ASH Annual Meeting Abstracts) 106(11): #3488
Year
2005
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

SWOG 0204; phase 2 trial of thalidomide (T) + dexamethasone (D) induction followed by tandem autotransplant (TAT) and prednisone (P) + T maintenance for multiple myeloma (MM)

Authors
MA Hussein;J McCoy;A Jakubowiak;BG Durie;JJ Crowley;B Barlogie
Journal / Conference
Blood (ASH Annual Meeting Abstracts) 106(11): #1169
Year
2005
Research Committee(s)
Myeloma
Study Number(s)
S0204

SNP genotypes as prognostic factors associated with staging in myeloma: the first combined SNP association analysis of SWOG, ECOG, and MRC clinical trials from the Bank on a Cure

Authors
B Van Ness;J Crowley;E Blood;E Rasmussen;C Ramos;S Grindle;G Morgan;D Johnson;A Hoering;P Greipp;B Barlogie;B Durie
Journal / Conference
Blood (ASH Annual Meeting Abstracts) 106(11): #3489
Year
2005
Research Committee(s)
Myeloma
Study Number(s)
SWOG-9321

Differential antigenic targets of anti-tumor immune response and selective immunity to stem cell associated group B SOX proteins in preneoplastic versus malignant gammopathy

Authors
R Spisek;L Chen;M Scanlan;A Simpson;G Ritter;E Rasmussen;J McCoy;A Murray;J Krasovsky;B Durie;J Crowley;A Mazumder;S Jagannath;B Barlogie;A Gure;M Dhodapkar
Journal / Conference
Blood (ASH Annual Meeting Abstracts) 106(11): #5116
Year
2005
Research Committee(s)
Myeloma
Study Number(s)
S0120

Cytogenetic studies of 539 chronic lymphocytic leukemia (CLL) patients

Authors
NA Heerema;G Lozanski;TS Lin;M Moran;MR Grever;JC Byrd
Journal / Conference
Blood 106(11):#1192
Year
2005
Research Committee(s)
Leukemia
Study Number(s)
E2997